• Robert Taylor, Joseph V Pergolizzi, R Amy Puenpatom, and Kent H Summers.
• NEMA Research, 840 111th Avenue North, Suite 9, Naples 34108-1877, FL, USA.
• Expert Rev Pharmacoecon Outcomes Res. 2013 Dec 1;13(6):725-34.

AbstractChronic pain patients may be subject to polypharmacy because of long-term pharmacological pain treatment and additional comorbidities. Many chronic pain patients expose themselves to potential drug-drug interactions (DDIs) and these interactions can have unintended and severe consequences. Prevalence and costs associated with DDIs are inconsistent and has led to an inadequate level of awareness among the medical community; therefore, it has become necessary to re-evaluate the rates of DDIs in chronic pain patients. Utilizing medical and prescription claims databases, five studies were conducted to assess the health care utilization of and associated financial payments for patients >18 years with chronic noncancer pain. The studies evaluated drug-drug exposures with the potential to cause DDIs specifically occurring through the CYP450 enzyme system. The studies reported that drug-drug exposures are prevalent, costly and can occur in any age group and that physicians should consider ways to limit their patients' exposure to potential DDIs.

15 keywords...

hide…